- Home
- FRPH vs AUTL Comparison
FRPH vs AUTL Comparison
Compare FRPH & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRPH | AUTL |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | 752 |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.6M | 596.2M |
| IPO Year | 1995 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FRPH | AUTL |
|---|---|---|
| Price | $22.29 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 86.3K | ★ 2.6M |
| Earning Date | 04-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,846,000.00 | $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.57 | ★ 496.00 |
| 52 Week Low | $20.53 | $1.18 |
| 52 Week High | $25.74 | $2.58 |
Technical Indicators
Market Signals| Indicator | FRPH | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 47.96 |
| Support Level | $21.87 | $1.37 |
| Resistance Level | $23.19 | $2.43 |
| Average True Range (ATR) | 0.50 | 0.11 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 45.08 | 4.17 |
Price Performance
Historical ComparisonAbout FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, industrial, and office (the Development Segment), and (iv) management of mixed-use residential/retail properties owned through joint ventures.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.